Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials
Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials
复制标题
DOI：
10.1111/j.1365-3156.2004.01342.x
复制
发表时间：
2004-12-01
影响因子：
3.3
通讯作者：
White, NJ
中科院分区：
文献类型：
--
作者：
Dondorp, AM;Newton, PN;White, NJ
目的了解东南亚地区抗疟假药的流行情况。设计横断面调查。在缅甸、老挝、越南、柬埔寨和泰国设立销售抗疟药的药店和商店。主要观察指标含青蒿素衍生物或甲氟喹的药品质量不合格比例。结果在购买的188包贴有“青蒿琥酯”标签的片剂中，53%不含青蒿琥酯。所有假冒的青蒿琥酯片剂都被贴上“桂林制药”的标签，而且假药的吸塑包装经过改进，通常很难与正品区分开来。没有发现其他青蒿素衍生物是假冒的。44份甲氟喹样本中，9%含有
Objective To assess the prevalence of counterfeit antimalarial drugs in Southeast (SE) Asia.Design Cross-sectional survey.Setting Pharmacies and shops selling antimalarial drugs in Myanmar (Burma), Lao PDR, Vietnam, Cambodia and Thailand.Main Outcome Measures Proportion of artemisinin derivatives or mefloquine containing drugs of substandard quality.Results Of the 188 tablet packs purchased which were labelled as 'artesunate' 53% did not contain any artesunate. All counterfeit artesunate tablets were labelled as manufactured by 'Guilin Pharma', and refinements of the fake blisterpacks made them often hard to distinguish from their genuine counterparts. No other artemisinin derivatives were found to be counterfeited. Of the 44 mefloquine samples, 9% contained